Showing results (21-30 of 6,499) with videos related to
Sort By:
Pageof 650
Cancer Immunology, Immunotherapy : CII|January 8, 2020
Comparable outcomes of nivolumab in patients with advanced NSCLC presenting with or without brain metastases: a retrospective cohort studyGuowei Zhang, Ruirui Cheng, Huijuan Wang, et al.Cancer Immunology, Immunotherapy : CII|June 20, 2022
Myeloid-derived suppressor cells cross-talk with B10 cells by BAFF/BAFF-R pathway to promote immunosuppression in cervical cancerDing Jianyi, Gan Haili, Yin Bo, et al.Cancer Immunology, Immunotherapy : CII|June 22, 2021
Immune checkpoint inhibitors-induced nephropathy: a French national surveyAlexandre O Gérard, Marine Andreani, Audrey Fresse, et al.Cancer Immunology, Immunotherapy : CII|June 23, 2021
A multi-center, single-arm, phase Ib study of pembrolizumab (MK-3475) in combination with chemotherapy for patients with advanced colorectal cancer: HCRN GI14-186Cameron J Herting, Matthew R Farren, Yan Tong, et al.Cancer Immunology, Immunotherapy : CII|June 23, 2021
T-cell responses and combined immunotherapy against human carbonic anhydrase 9-expressing mouse renal cell carcinomaMamoru Harada, Yuichi Iida, Hitoshi Kotani, et al.Cancer Immunology, Immunotherapy : CII|December 16, 2022
The common HLA class I-restricted tumor-infiltrating T cell response in HPV16-induced cancerSaskia J Santegoets, Marij J P Welters, Deborah S Schrikkema, et al.Cancer Immunology, Immunotherapy : CII|January 1, 1987
Infiltration of primary and metastatic melanomas with macrophages of the 25F9-positive phenotypeE B Bröcker, G Zwadlo, L Suter, et al.Cancer Immunology, Immunotherapy : CII|January 10, 2023
Determinants of activity and efficacy of anti-PD1/PD-L1 therapy in patients with advanced solid tumors recruited in a clinical trials unit: a longitudinal prospective biomarker-based studyJavier García-Corbacho, Alberto Indacochea, Azucena E González Navarro, et al.Cancer Immunology, Immunotherapy : CII|November 28, 2022
Treatment options for unresectable hepatocellular carcinoma with hepatitis virus infection following sorafenib failureXiaomi Li, Xiaoyan Ding, Wei Li, et al.Cancer Immunology, Immunotherapy : CII|May 4, 2022
Inability of ovarian cancers to upregulate their MHC-class I surface expression marks their aggressiveness and increased susceptibility to NK cell-mediated cytotoxicityNishant Chovatiya, Kawaljit Kaur, Sara Huerta-Yepez, et al.Pageof 650